We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
RANDOX LABORATORIES

Download Mobile App




Multiplex Assay Detects Pathogens in NF Patients

By LabMedica International staff writers
Posted on 23 Apr 2019
Print article
Image: An area of mild erythema around varicella lesion on the thigh of a young boy progressed to necrotizing fasciitis caused by group A Streptococcus (Photo courtesy of Dr. E. P. Dellinger, MD).
Image: An area of mild erythema around varicella lesion on the thigh of a young boy progressed to necrotizing fasciitis caused by group A Streptococcus (Photo courtesy of Dr. E. P. Dellinger, MD).
Necrotizing fasciitis (NF) is a life-threatening deep soft tissue infection characterized by rapidly progressive necrosis of the fascia and the adjacent soft tissues. NF of the extremities is associated with high mortality rates, and immediate surgical intervention is required upon detection of NF infections.

Early diagnosis and bacterial identification are essential for adequate surgical treatment and appropriate antibiotic administration in patients with NF. The clinical signs and symptoms of NF caused by Gram-positive and Gram-negative microorganisms are characteristically indistinguishable at the time of presentation. Moreover, it takes 3 to 4 days to obtain the results of microbiological analysis and antimicrobial sensitivity testing of the specimens.

Scientists from Chang Gung Memorial Hospital (Taoyuan City, Taiwan) collected samples from 99 patients with surgically confirmed NF of the extremities who were hospitalized consecutively between June 2015 and November 2017. Two sets of blood and tissue samples were collected from all patients; one set was sent to a microbiology laboratory for bacterial identification and the other set was sent to an immunohistochemistry laboratory for polymerase chain reaction (PCR) amplification.

The culture specimens were obtained from the infected wounds or the blood, and were identified by microbiological evaluation. Genomic bacterial DNA extraction was performed and 16S rDNA universal PCR was performed for each sample to validate the results of the multiplex PCR assay. Total genomic DNA was purified using a Geneaid Bacteria Genomic DNA Kit and amplified. PCR amplicons were analyzed by electrophoresis in 2% agarose gel.

The multiplex PCR results for the blood samples showed negative findings. The multiplex PCR results for the tissue specimens showed 28 positive findings. Fourteen (87.5%) of the 16 Vibrio vulnificus culture-positive tissue specimens, six (75%) of the eight Aeromonas hydrophila culture-positive tissue specimens, and four (100%) of the four methicillin-resistant Staphylococcus aureus (MRSA) culture-positive tissue specimens were positive by PCR. Similarly, two (100%) of the group A Streptococcus and two (100%) of the group B Streptococcus were PCR-positive.

The authors concluded that the accuracy rate of the multiplex PCR presenting positive results in these culture-positive tissue samples was 87.5% (28/32). This suggests that multiplex PCR of tissue specimens may be a useful and rapid diagnostic tool for the detection of these lethal microorganisms in patients with NF. The study was published in the April 2019 issue of the International Journal of Infectious Diseases.

Related Links:
Chang Gung Memorial Hospital

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Real-time PCR System
GentierX3 Series

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Molecular Diagnostics

view channel
Image: A blood test could predict lung cancer risk more accurately and reduce the number of required scans (Photo courtesy of 123RF)

Blood Test Accurately Predicts Lung Cancer Risk and Reduces Need for Scans

Lung cancer is extremely hard to detect early due to the limitations of current screening technologies, which are costly, sometimes inaccurate, and less commonly endorsed by healthcare professionals compared... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: Exosomes can be a promising biomarker for cellular rejection after organ transplant (Photo courtesy of Nicolas Primola/Shutterstock)

Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies

Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more

Pathology

view channel
Image: The QIAseq xHYB Mycobacterium tuberculosis Panel uses next-generation sequencing (Photo courtesy of 123RF)

New Mycobacterium Tuberculosis Panel to Support Real-Time Surveillance and Combat Antimicrobial Resistance

Tuberculosis (TB), the leading cause of death from an infectious disease globally, is a contagious bacterial infection that primarily spreads through the coughing of patients with active pulmonary TB.... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.